Douglas S Daniels

Title: Douglas S. Daniels: Innovator in Fibroblast Growth Factor Research

Introduction

Douglas S. Daniels is a prominent inventor based in Arlington, MA (US). He has made significant contributions to the field of biotechnology, particularly in the development of fusion proteins related to fibroblast growth factor 21 (FGF21). With a total of 8 patents to his name, his work has the potential to impact the treatment of various metabolic disorders.

Latest Patents

One of his latest patents is focused on "Fibroblast growth factor-21-Fc fusion proteins." This invention relates to the identification of fusion proteins comprising polypeptide and protein variants of FGF21 with improved pharmaceutical properties. The patent also discloses methods for treating FGF21-associated disorders, including metabolic conditions. Another significant patent is for "Nucleic acids encoding FGF21-Fc fusion proteins." This invention pertains to nucleic acids that encode fusion proteins comprising polypeptide and protein variants of FGF21, along with vectors and host cells that contain these nucleic acids and methods for producing the fusion proteins.

Career Highlights

Throughout his career, Douglas has worked with notable companies such as Novartis AG and Irm LLC. His experience in these organizations has allowed him to refine his expertise in biotechnology and patent development.

Collaborations

Douglas has collaborated with several professionals in his field, including Brian R. Boettcher and Shari Lynn Caplan. These collaborations have likely contributed to the innovative nature of his work and the successful development of his patents.

Conclusion

Douglas S. Daniels is a key figure in the advancement of fibroblast growth factor research, with a strong portfolio of patents that reflect his innovative contributions to biotechnology. His work continues to pave the way for new treatments in metabolic disorders.